IL17A and Parkinson disease: Would ropinirole or pramipexole modulate IL-17 and IFN-γ production by T cells of PD patients at therapeutically relevant concentrations, DA agonists in PD could possibly shift from mere DA substitutes to immunomodulating drugs targeting Th17 and Th1 mechanisms potentially involved in neuroinflammation underlying PD neurodegeneration.